Research programme: Fabry's disease plant-produced protein therapeutics - iBio
Alternative Names: plant-produced human alpha galactosidase A; α-Gal ALatest Information Update: 15 Sep 2016
At a glance
- Originator iBio Inc
- Class Enzymes; Proteins
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Fabry's disease
Most Recent Events
- 15 Sep 2016 Discontinued - Preclinical for Fabry's disease in USA (unspecified route) (iBio website; September 2016)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Fabry's-disease in USA